R&D News | pharmaphorum

News

AZ forges ever-closer ties with China's CSPC Pharma

AstraZeneca has returned to China's CSPC Pharma to fill its R&D pipeline, reaching a new $1.77bn agreement to develop drugs for kidney diseases.

News

Roche's KRAS drug tops its rivals in lung cancer trial

Roche has thrown down the gauntlet to Amgen and Bristol Myers Squibb with new phase 3 data for its experimental KRAS G12C inhibitor, divarasib.

News

Ipsen's M&A team strikes again, adding Memo in $700m deal

Ipsen will pay up to €700m to take control of Memo Therapeutics and its drug for BK polyomavirus, which can lead to the failure of kidney transplants.

News

Anthropic launches Claude Science for pharma researchers

Anthropic had made a big life sciences play with the launch of Claude Science, an AI 'workbench' for researchers involved in drug discovery.

News

Digital brain inside human head concept for Vistagen

Despite study bust, Vistagen still hopes to file anxiety dru...

Vistagen has chalked up another trial failure for fasedienol, its drug candidate for social anxiety disorder.

News

Drugmakers asked to defend Chinese trials; reports

The House China Select Committee has quizzed MSD, AbbVie, Bristol Myers Squibb, and Pfizer about the ethics of clinical trials run in China.

AZ forges ever-closer ties with China's CSPC Pharma

Roche's KRAS drug tops its rivals in lung cancer trial

Ipsen's M&A team strikes again, adding Memo in $700m deal

Anthropic launches Claude Science for pharma researchers

Despite study bust, Vistagen still hopes to file anxiety dru...

Drugmakers asked to defend Chinese trials; reports

ASCO 2026: All about DNA damage response, with Luke Piggot

Discover a new era of healthcare panel engagement: Grounded ...

News

Editor's Picks